Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Anaemia associated with intrinsic renal disease Clinical criteria: Patient must require transfusion, AND Patient must have a haemoglobin level of less than 100 g per L, AND Patient must have intrinsic renal disease, as assessed by a nephrologist.
“Erythropoietin is a growth factor for erythroid development. It is produced in the kidney and released into the bloodstream in response to hypoxia, interacting with erythroid progenitor cells to increase red blood cell production.”
“Following IV administration in CKD patients, the observed terminal elimination half-life (t 1/2 ) for Mircera was 134 hours, and the total systemic clearance was 0.494 mL/hr/kg. Following SC administration the t 1/2 was 139 hours in dialysis patients and 142 hours in patients not on dialysis.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.